Navigate today’s most pressing health industry challenges with a leading global expert by your side.
ACO utilization & cost evaluation
Healthcare cost modeling
Insurance risk assessment
Medicare plan selection solution
Healthcare risk adjustment
Pharmaceutical claims analytics
Meet growing needs for innovative insurance solutions while increasing operational health and improving compliance.
Financial modeling & industrialization
Retirement & Benefits
Deliver on the promises of the past and create smart solutions for the future.
Compensations & benefits
Benefit plan evaluation
Manage complex risks using data-driven insights, advanced approaches, and deep industry experience.
Auto policy underwriting
Software performance enhancement
Mortgage platform for investments & reinsurance
Solvency II reporting & compliance
This is a place where your ideas and insights make an impact. Where an independent, entrepreneurial spirit is an advantage. And where diversity of thought and experience makes us who we are.
Data-driven insight. Deep expertise. Transformative innovation. Since 1947, Milliman has delivered intelligent solutions to improve health and financial security.
Mental & behavioural health
Milliman consultants are well versed in the intricacies of mental and behavioural health coverage and legislation and can provide guidance to clients on cost, utilisation, and more.
We test health plan compliance with the quantitative and nonquantitative requirements of MHPAEA. Quantitative testing checks that financial requirements and quantitative treatment limits for mental health/substance use disorder benefits are no more restrictive than predominant levels for medical/surgical benefits. We also test compliance with nonquantitative treatment limits, including care management processes.
We evaluate and forecast the potential impact of current or future mental health and substance use disorder policy as well as quantify the prevalence, variation, or impact of emerging behavioural health challenges.
We evaluate the economic impact of integrated care, including developing financial support and staffing models, calculating return on investment, and researching the impact of medical and behavioural comorbidities on total cost of care.
We analyse outcomes of population health, disease management, substance use treatment, and other types of behavioural programs with the goal of identifying areas of improvement in program design and delivery.
We research aspects of the opioid crisis in the U.S., including prescribing patterns, ER usage, comorbidities, and excess costs. We also support and evaluate programs and other responses to the opioid epidemic.
We develop models to predict underdiagnosed or undermanaged mental health and substance use disorders from prior healthcare utilisation patterns, demographics, prescription drug use, and other diagnoses.
We perform analyses such as projecting health costs and utilisation by service category, evaluating budgets and rate adequacy, and estimating cost savings from programs or other interventions.
We design elements of risk management for behavioural healthcare providers in their contracting efforts, including but limited to capitation rates, risk sharing, incentive payments, and performance guarantees.
We analyse provider fee schedules for behavioural providers over time and compare them to area-specific and national benchmarks.
We evaluate behavioural healthcare costs and utilisation metrics by service category against area-specific and national carrier data.
We perform financial analyses to project future costs and evaluate the adequacy of behavioural healthcare rates.
We develop healthcare utilisation and cost projections for baseline periods and intervention periods to demonstrate cost effectiveness of new initiatives for payer contracts or government entities.
What has happened to utilization and costs for mental health and substance use disorder benefits as the mental health parity laws and associated rules were slowly rolled out?
Beyond the impact of the final rule, IMDs will continue to be a topic of interest to state policy makers as they bolster the continuum of behavioral health and substance use disorder services.
This study assesses the prevalence and costs associated with comorbid chronic medical conditions among individuals with diagnosed opioid use disorder (OUD) and opioid super-users without diagnosed OUD.
A discussion of trends, including recent federal and state laws affecting health insurance benefits for transgender individuals and health insurance clinical coverage policies related to gender reassignment surgery.
This paper presents a comparison of opioid prescription drug patterns among diagnosed and non-diagnosed opioid use disorder populations.
Over 25 million American adults report suffering from daily chronic pain. The increasing use of opioids in recent years has taken a human toll, leading to a rising number of overdose deaths and diagnoses of opioid use…
Many patients with opioid use disorder have complex healthcare needs, contributing to their significant healthcare costs.
The state of Colorado has implemented behavioral healthcare in primary medical care settings under a Centers for Medicare and Medicaid Services State Innovation Model Award.
Nonquantitative treatment limitations continue to be a source of difficulty for many health plans in attaining compliance with the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008.
Final rules clarify how to comply with provisions of the Mental Health Parity and Addiction Equity Act of 2008.
Stoddard Davenport and Joseph Boschert discuss their latest research on opioid use in the United States, including underdiagnoses and how advanced analytics can help predict whether a patient may develop opioid use disorder.
We’re here to help you break through complex challenges and achieve next-level success.